

Creative Biolabs' Dual-Action Antibody Webinar Ignites Biotech Buzz

Creative Biolabs hosted a webinar about a multi-engager antibody, which heated up the versatile antibody candidate market including bispecifics.

SHIRLEY, NY, UNITED STATES, June 19, 2025 /EINPresswire.com/ -- May 22's webinar wasn't just another science talk—it was a mic-drop moment. Researchers worldwide tuned in to watch Generation of a Dual-Function Multi-Engager Antibody for Simultaneous Targeting NK Cells and Tumor Cells, a hot-ticket presentation that put dual-targeting antibodies squarely in the biotech limelight.



With registrations soaring and Q&A stretching past schedule, one thing is clear—multifunctional antibodies are stealing the spotlight.

The Bispecific Boom: Why Dual Targeting is Pharma's Next Big Thing

Move over, monoclonals—bispecific antibodies are reshaping cancer immunotherapy. By binding two targets at once, the "smart missiles" offer a double whammy against hard-to-treat cancers. As of March 2025, more than 600 bispecific candidates are now in clinical trials. Creative Biolabs is riding the wave with its tailor-made platforms, offering tailored design, robust manufacturing, and flexible formatting options for research, preclinical, and IND-stage projects, with the aim of transforming bispecific antibody design from a molecular puzzle into a plug-and-play revolution.

Products That Hit the Sweet Spot

Whether for startups just embarking on the bsAb exploration or pharma giants preparing for the clinic, Creative Biolabs gives a hand by providing custom bispecific antibody development to

offer full-spectrum support—from concept to candidate. Researchers can choose from a wide array of platforms tailored to function and format or pick up their favorite from a bank of proprietary reagents of miscellaneous formats.

* [Tandem scFv](#)

Extensively used in cancer immunotherapy, the tandem scFv product line covers mainstream research targets, including CD3, PSA, CD30, and CD28 with a close proximity.

Recombinant Anti-CD3 x Anti-PSA Bispecific Antibody (Tandem scFv)

Recombinant Anti-CD3 x Anti-PLAP Bispecific Antibody (Tandem scFv)

Recombinant Anti-CD3 x Anti-EGFR Bispecific Antibody (Tandem scFv)

Recombinant Anti-CD28 x Anti-CSPG4 Bispecific Antibody (Tandem scFv)

* [Tandem Fab](#)

Tandem Fabs are a class of Fab-based bispecific antibody fragments targeting different epitopes, which have monovalent for each antigen specificity and are more thermally stable than the corresponding scFvs.

Recombinant Anti-CD3 x Anti-PSCA Bispecific Antibody (Tandem Fab)

Recombinant Anti-CD3 x Anti-PSA Bispecific Antibody (Tandem Fab)

Recombinant Anti-CD28 x Anti-FOLR1 Bispecific Antibody (Tandem Fab)

* [Tandem scFv-Fc](#)

Need stability and Fc-mediated functions? Check out the Tandem scFv-Fc format for plug-and-play versatility. Creative Biolabs supplies such bispecifics presenting 2 + 2 antigen-binding valency and Fc-mediated functions, such as ADCC, ADCP, and long half-life.

Recombinant Anti-CD3 x Anti-PSA Bispecific Antibody (Tandem scFv-Fc)

Recombinant Anti-CD3 x Anti-p97 Bispecific Antibody (Tandem scFv-Fc)

Recombinant Anti-B cell lymphoma BCL1 Idiotypic x Anti-CD64 Bispecific Antibody (Tandem scFv-Fc)

"Each format is backed by in-house protein engineering, expression optimization, and analytical support," the rep says. "No guesswork, no hold-ups."

Visit <https://www.creative-biolabs.com/bsab/> and learn more.

Next Up: A Full Conference Circuit

With the bispecific pipeline expanding fast, Creative Biolabs is hitting the road. Catch their experts at the upcoming events in Season 3 to learn how their bsAb platforms are reshaping the therapeutic frontier:

August 27–29, 2025 | 5th Oligonucleotides for CNS Summit

September 9–11, 2025 | 16th Annual World Bispecific Summit

September 23–25, 2025 | 7th Exosome Based Therapeutic Development Summit

About

For those researchers, whether exploring bispecifics for oncology, autoimmunity, or CNS disorders, Creative Biolabs is ready to help them hit the ground running with peer-recognized technical support and first-rate research tools.

Candy Swift

Creative Biolabs

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/823266475>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.